Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4
MCT1 and MCT4 are overexpressed in CTCs from NSCLC patients, supporting their potential as prognostic biomarkers and therapeutic targets.
Authors
- Galatea Kallergi (ORCID: https://orcid.org/0000-0001-9825-3871)
- Evangelia Pantazaka (ORCID: https://orcid.org/0000-0001-6737-8428)
- Lianidou ES
- A. Kotsakis
- Vassilis Georgoulias (ORCID: https://orcid.org/0000-0003-2218-2522)
- Karolina Mangani
- Athina Markou
Institutions
- University of Patras (GR)
- National and Kapodistrian University of Athens (GR)
- University Hospital of Larissa (GR)
- Hellenic Oncology Research Group (GR)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/17588359261416422
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00